– Claus Andersson, PhD, joins Rewind’s Board of Administrators
Leuven, Belgium, January 25, 2023 — Rewind Therapeutics, an organization growing first-in-class therapies for demyelination-associated ailments, at this time introduced that it has raised extra funding, with Sunstone Life Science Ventures A/S becoming a member of as a brand new investor and with participation of current traders Boehringer Ingelheim Enterprise Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Claus Andersson, PhD, Common Associate at Sunstone Life Science Ventures A/S, will be a part of Rewind Therapeutics’ Board of Administrators. Monetary particulars of the transaction weren’t disclosed.
The proceeds will probably be used to advance Rewind Therapeutics’ lead program into medical growth and additional broaden the Firm’s pipeline of drug candidates designed to revive the remyelination operate of the central nervous system (CNS). Myelin types a protecting layer round neurons and is important for his or her correct functioning. Neurodegenerative issues equivalent to a number of sclerosis are related to a broken, deteriorating myelin sheath, which finally results in a variety of signs equivalent to melancholy, nervousness, irritability, and even loss of life as a result of a breakdown of the important neurological features.
“We’re delighted to welcome Sunstone Life Science Ventures as a brand new investor alongside the continued assist by our current investor syndicate,” mentioned Anja Harmeier, Chief Government Officer at Rewind Therapeutics. “The extra financing not solely strengthens our top-tier investor base, but additionally permits us to speed up the development of our lead program into medical growth. Moreover, we look ahead to working with Claus Andersson as a brand new member of our Board of Administrators. “
“Halting and even reversing demyelination is a difficult job. The information generated by Rewind Therapeutics to this point helps a very novel mechanism of motion and can permit the Firm to provoke medical trials in key CNS indications,” mentioned Claus Andersson, PhD, Common Associate at Sunstone Life Science Ventures A/S. “Furthermore, Rewind has a robust patent property and a group with lengthy analysis and growth experience within the area of remyelination therapeutics. The mix of this intensive trade experience and the excessive unmet medical want in neurogenerative issues has satisfied us to affix forces with Rewind´ s current, internationally famend investor syndicate.”
Demyelinating ailments equivalent to a number of sclerosis have an effect on hundreds of thousands of sufferers worldwide. Rewind’s method is predicated on guaranteeing correct functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), each of that are drivers of the myelination course of. The Firm’s aim is to ascertain a novel therapeutic precept that’s universally relevant to all demyelination ailments. This offers important therapeutic potential for treating a broad vary of demyelination-inducing circumstances.
About Rewind Therapeutics
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the method of remyelination in sufferers affected by main debilitating ailments equivalent to a number of sclerosis, optic neuritis or nerve accidents. A typical function of those sicknesses is the lack of the myelin sheath, a protecting cowl wrapped across the nerves. Repairing or re-installing this sheath (ie, remyelination) is a vital issue for halting or reversing illness development and even curing these ailments. Rewind’s group has intensive R&D experience and has constructed a robust patent property for growing novel remyelination therapeutics. Based mostly in Leuven, Belgium, Rewind is backed by top-tier life science traders equivalent to Boehringer Ingelheim Enterprise Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/KU Leuven.
About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an unbiased European enterprise capital funding agency based in 2007 by a world group of trade specialists with mixed entrepreneurial, operational and monetary expertise. Managing complete funds of €500 million, Sunstone Life Science Ventures focuses on growing and increasing early-stage Life Science corporations with robust potential to attain international
success of their markets. Because the inception, Sunstone Life Science Ventures has invested in additional than 50 corporations within the areas of prescription drugs, medical applied sciences and diagnostics, and has accomplished greater than 20 profitable IPOs and enormous M&A transactions. For extra data, please go to: https://sunstone.eu/
For additional data please contact:
Chief Government Officer
Dr Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68